scholarly journals 11 REM sleep impairment is reverted by absence-seizure treatment in a SYNGAP1 haploinsufficiency rat model of autism and intellectual disability

Author(s):  
Ingrid Buller-Peralta ◽  
Katerina Hristova ◽  
Alejandro Bassi ◽  
Sally Till ◽  
Adrian Ocampo-Garces ◽  
...  
2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Vishakh Iyer ◽  
Quynh Vo ◽  
Anthony Mell ◽  
Siven Chinniah ◽  
Ashley Zenerovitz ◽  
...  

AbstractRapid-eye-movement (REM) sleep without atonia (RSWA), a marker of REM sleep behavior disorder (RBD), is frequently comorbid with Parkinson’s disease (PD). Although rodent models are commonly used for studying PD, the neurobiological and behavioral correlates of RBD remain poorly understood. Therefore, we developed a behavior-based criteria to identify RSWA in the hemiparkinsonian rat model of PD. Video recordings of rats were analyzed, to develop a criteria consisting of behavioral signs that occurred during polysomnographically confirmed epochs of sleep-wake stages. The sleep-slouch, a postural shift of the body or head caused only by gravity, was identified as a unique behavioral sign of REM sleep onset and was altered in hemiparkinsonian rats during RSWA. There was a significant correlation between the behavior-based criteria and polysomnograms for all sleep-wake stages in control but not hemiparkinsonian rats indicating a deterioration of sleep-wake architecture in parkinsonism. We then tested the efficacy of levodopa in ameliorating RSWA using intermittent and around-the-clock (ATC) dosing regimens. ATC levodopa dosing at 4 mg/kg for 48 h caused a significant reduction of RSWA as measured by polysomnography and the behavioral-based criteria along with an amelioration of forelimb motor deficits. Our findings show that the phenomenological correlates of RSWA can be reliably characterized in the hemiparkinsonian rat model. ATC levodopa administration ameliorates RSWA in this model without deleterious consequences to the overall sleep-wake architecture and therapeutic benefits for parkinsonian motor deficits. These findings suggest that further study may allow for the application of a similar approach to treat RBD in PD patients.


Author(s):  
Markus Reuber ◽  
Gregg H. Rawlings ◽  
Steven C. Schachter

This chapter explores how a Neurologist treated a patient who was referred by a neuropediatric hospital with a diagnosis of generalized epilepsy, which had probably started in infancy with absence seizures. Moderate intellectual disability had also been noticed at that time. In her early adolescence, she started to present with generalized tonic-clonic seizures (GTCS), which were not preceded by any aura. She became seizure-free with a combination of antiepileptic medication. However, one year before the patient’s first consultation in the Neurologist’s office, her seizures had recurred, but the seizure semiology had changed: she would call her father and report vertigo and headache before seeming to loose consciousness. In a consultation without her parents, the patient told the Neurologist how she struggled with the responsibility of being independent of her parents. In this respect, it is interesting to note that the patient regularly experienced an absence seizure on days when aspects of her first vacation with her friends (and without her parents) were discussed in the family.


2014 ◽  
Vol 226 ◽  
pp. 33-41 ◽  
Author(s):  
Marina V. Sysoeva ◽  
Evgenia Sitnikova ◽  
Ilya V. Sysoev ◽  
Boris P. Bezruchko ◽  
Gilles van Luijtelaar

Author(s):  
Ryo Deguchi ◽  
Moe Fujimoto ◽  
Hiroshi Sekiyama ◽  
Shigehito Sawamura

AbstractPatients with chronic pain develop peripheral neuropathy and experience sleep disturbance. Yokukansan is used to treat insomnia and control neuropathic pain. We studied if Yokukansan affects neuropathic pain and sleep disturbance using a rat model of chronic constriction injury (CCI). Male Wistar rats (4-week age) were divided into the following groups (n = 7, per group): CCI rats fed normal chow (CCI-0); CCI rats fed powdered chow mixed with 1% Yokukansan (CCI-1); CCI rats fed powdered chow mixed with 3% Yokukansan (CCI-3); and sham-operated control rats fed normal chow (SHAM). We examined sleep duration and quality using electroencephalograms and assessed pain using the von Frey and Hargreaves tests. Results were analyzed by one-way analysis of variance and Bonferroni post hoc tests. The CCI-0 group exhibited an increased wake period, decreased non-rapid eye movement (REM) sleep time, and no change in REM sleep time in comparison to the SHAM group. The CCI-1 group exhibited a decreased wake period, increased non-REM sleep time, and no change in REM sleep time compared to the CCI-0 group. The CCI-3 group exhibited increased non-REM sleep time but no changes in wake and REM sleep times compared to the CCI-1 group. The von Frey and Hargreaves test findings revealed an increase in the pain threshold in the CCI-1 group compared to the CCI-0 group. There was no difference in pain threshold between the CCI-1 and CCI-3 groups. In our rat model of CCI, sleep disturbance was reflected. Yokukansan inhibited CCI-induced sleep disturbance.


2008 ◽  
Vol 7 (S1) ◽  
Author(s):  
Schwann Shariati Rad ◽  
Marjan Nassiri Asl ◽  
Farzaneh Zamansoltani
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document